Abstract:The concept of chimeric antigen receptor (CAR) T cell therapy emerged from cancer immunotherapy and has been rapidly adapted and developed for the treatment of autoimmune, especially B-cell-driven, diseases since the first publication of an article featuring a patient with systemic lupus erythematosus in 2021. Phase II studies are about to start, but up to now, only case reports and small series have been published. In contrast to hemato-oncological diseases, where an aggressive response to malignant cells and long-lasting persistence of CAR T cells has been aimed at and observed in many patients, this is not the case with autoimmune diseases but might not be necessary to control disease. Future studies will focus on the optimal target but also on the optimal level of immunogenicity. The latter can be influenced by numerous modulations that affect not only cytokine release but also regulation. In addition, there are potential applications in regulatory cells such as CAR regulatory T cells (Treg). The question of toxicity reduction must also be addressed, as long-term complications such as the potential development of malignant diseases, infections, or cytopenia must be considered even more critically in the area of autoimmune diseases than is the case for patients with oncologic diseases. Alternative antibody-based therapies using the same target (e.g., CD3/CD19 bispecific targeting antibodies) have not been used in these patients and might also be considered in the future. In conclusion, CAR T cell therapy represents a promising therapeutic approach for autoimmune diseases, offering a targeted strategy to modulate immune responses and restore immune tolerance.

Anti-CD20–mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives

B cell depletion therapy in autoimmune diseases.

B cell depletion therapies in autoimmune disease: advances and mechanistic insights

B-Cell Depletion and Repopulation in Autoimmune Diseases

Cutting-edge approaches to B-cell depletion in autoimmune diseases

B-cell depletion in autoimmune diseases

A new perspective on therapies involving B-cell depletion in autoimmune diseases

Translational Mini‐Review Series on B Cell‐Directed Therapies: The pathogenic role of B cells in autoantibody‐associated autoimmune diseases – lessons from B cell‐depletion therapy

CD20+ B Cell Depletion in Systemic Autoimmune Diseases: Common Mechanism of Inhibition or Disease-Specific Effect on Humoral Immunity?

B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?

B Cell Modulation Strategies in Autoimmune Diseases: New Concepts

Targeting B cells and plasma cells in autoimmune diseases: from established treatments to novel therapeutic approaches

Long-Lived Plasma Cells in Autoimmunity: Lessons from B-Cell Depleting Therapy

The quest for personalized B-cell depletion therapy in rheumatic disease

B cell-targeted therapies in autoimmunity: rationale and progress

Targeting B Cells and Plasma Cells in Autoimmune Diseases

Sequelae of B-Cell Depleting Therapy: An Immunologist's Perspective

CAR T cells for treating autoimmune diseases

Anti-B cell therapy (Rituximab) in the treatment of autoimmune diseases

Anti-CD20 treatment for B-cell malignancies: current status and future directions

The Future of CAR T Therapeutics to Treat Autoimmune Disorders